60 Degrees Pharmaceuticals to Present at H.C. Wainwright Conference
News provided by60 Degrees Pharmaceuticals, Inc · 1 min read
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a pharmaceutical company focused on developing new medicines for vector-borne diseases, will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.
On September 11, 2026, at 7:00 a.m. Eastern Time, a pre-recorded presentation will be available on demand to registered attendees and the general public via the H.C. Wainwright conference portal. The presentation will provide an overview of the company’s programs and initiatives aimed at the development and commercialization of medicines for vector-borne diseases.
During the conference, 60 Degrees Pharmaceuticals’ management will be available for one-on-one meetings with institutional investors and other participants. Interested parties are encouraged to submit meeting requests through the H.C. Wainwright conference platform.
The company’s presentation will cover its current initiatives, including its lead product, ARAKODA® (tafenoquine), which was approved by the U.S. Food and Drug Administration (FDA) for malaria prevention in 2018. 60 Degrees Pharmaceuticals is currently conducting three active clinical trials for babesiosis, an emerging tick-borne disease. The company also collaborates with leading research and academic organizations to advance the science around vector-borne diseases.
Founded in 2010, 60 Degrees Pharmaceuticals is headquartered in Washington, D.C., with a subsidiary in Australia. The company’s commercial products include ARAKODA, sold in the U.S. and Australia, and continues to explore new indications for its lead product.
The company’s future success depends on its ability to develop, obtain FDA approval for, and commercialize non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) and Celgosivir. The company emphasizes that there is substantial uncertainty regarding its ability to continue as a going concern and faces risks related to its research and development efforts.